Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068926 | 1.00 | AXL (0.55) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL21912529 | 0.86 | AXL (0.51) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL22430456 | 0.86 | AXL (0.51) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL12491066 | 0.86 | AXL (0.51) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL27590571 | 0.86 | AXL (0.51) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL26176435 | 0.83 | GPR84 (0.51) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL9046899 | 0.83 | AXL (0.49) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL30099046 | 0.82 | AXL (0.36) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL14845836 | 0.82 | MET (0.49) | AXLGPR84LRRK2KMT2AMAP2K1 | |
| SCHEMBL27678813 | 0.82 | MAP2K1 (0.54) | AXLGPR84LRRK2KMT2AMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912703-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090118301-A1 | Compositions and Methods for Treating Cancer | ARBOR VITA CORPORATION (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118301-A1 | Compositions and Methods for Treating Cancer | ARBOR VITA CORPORATION (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20080021026-A1 | BENZOTHIOPHENE INHIBITORS OF RHO KINASE | Kahraman, Mehmet (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021026-A1 | BENZOTHIOPHENE INHIBITORS OF RHO KINASE | Kahraman, Mehmet (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007138472-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | AXL 2842/4885GPR84 95/4885LRRK2 1079/4885 |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | AXL 4422/4885GPR84 3348/4885LRRK2 3990/4885 |
| US-20080021026-A1 | BENZOTHIOPHENE INHIBITORS OF RHO KINASE | RHOT2, ROCK2, ROCK1 | AXL 3439/4885GPR84 3273/4885LRRK2 245/4885 |
| US-11912703-B2 | 6-azaindole compounds | TLR7, TLR9, TLR5 | AXL 2567/4885GPR84 181/4885LRRK2 921/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | AXL 3932/4885GPR84 1417/4885LRRK2 972/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | AXL 1530/4885GPR84 85/4885LRRK2 228/4885 |
| US-20090118301-A1 | Compositions and Methods for Treating Cancer | BRCA1, CA13, CA7 | AXL 4548/4885GPR84 4079/4885LRRK2 4725/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | AXL 2020/4885GPR84 84/4885LRRK2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.